Company intelligence / Profile preview

Stiftung MBF

Ambler, Pennsylvania, United Statesstiftung-mbf.ch ↗

Ownership: Private
Development stage: Other

Overview

MBF Therapeutics has developed a proprietary DNA vaccine platform called T-Max™, with its lead product being an adenoviral-vectored canine melanoma vaccine that has completed a Phase I study demonstrating safety and robust immune response. The company also focuses on vaccines against major infectious diseases such as African swine fever and PRRS in swine. Most programs remain preclinical or early clinical.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA vaccineAdenoviral vectorGene-based checkpoint inhibitor
Industry: Veterinary

Beyond the preview

Go deeper on Stiftung MBF.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stiftung MBF.

Explore the full profile